Climb Bio, Inc. CLYM Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Climb Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Climb Bio, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Climb Bio, Inc.'s additional paid-in capital?
- Climb Bio, Inc. (CLYM) reported additional paid-in capital of $451.37M in Q1 2026.
- How has Climb Bio, Inc.'s additional paid-in capital changed year-over-year?
- Climb Bio, Inc.'s additional paid-in capital increased by 1.7% year-over-year, from $443.75M to $451.37M.
- What is the long-term trend for Climb Bio, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Climb Bio, Inc.'s additional paid-in capital has grown at a 169.7% compound annual growth rate (CAGR), from $3.15M to $449.76M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.